Myasthenia Gravis Thymus: Complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status

American Journal of Pathology

Volumn 171, Issue 3, 2007, Pages 893-905

  Leite, Maria I ^a   Jones, Margaret ^b   Ströbel, Philipp ^c   Marx, Alexander ^c   Gold, Ralf ^c   Niks, Erik ^d   Verschuuren, Jan J G M ^d   Berrih Aknin, Sonia ^e   Scaravilli, Francesco ^f   Canelhas, Aurea ^g   Morgan, B Paul ^h   Vincent, Angela ^a   Willcox, Nick ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^g UNIVERSITY OF PORTO   (Portugal)

^h CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD59 ANTIGEN; CHOLINERGIC RECEPTOR; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5A; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; PROTEIN SUBUNIT;

ARTICLE; B LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTROMYOGRAPHY; EPITHELIUM CELL; FOLLICULAR DENDRITIC CELL; GERMINAL CENTER; HUMAN; HUMAN TISSUE; MACROPHAGE; MAJOR CLINICAL STUDY; MYASTHENIA GRAVIS; MYOID CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROLOGY; THYMOCYTE; THYMUS; THYMUS HYPERPLASIA; UPREGULATION;

EID: 34548863119     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2007.070240     Document Type: Article

References (60)

1. Vincent A: Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002, 2:797-804
2. Tzartos SJ, Barkas T, Cung MT, Mamalaki A, Marraud M, Orlewski P, Papanastasiou D, Sakarellos C, Sakarellos-Daitsiotis M, Tsantili P, Tsikaris V: Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev 1998, 163:89-120
3. Drachman DB, Adams RN, Josifek LF, Self SG: Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 1982, 307:769-775
4. Engel AG, Lambert EH, Howard FM: Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 1977, 52:267-280
5. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A: Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365-368
6. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, Marino M, Bartoccioni E: Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003, 126:2304-2311
7. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A: Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003, 60:1978-1980
8. McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, Vincent A: Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004, 55:580-584
9. Ohta K, Shigemoto K, Kubo S, Maruyama N, Abe Y, Ueda N, Fujinami A, Ohta M: MuSK Ab described in seropositive MG sera found to be Ab to alkaline phosphatase. Neurology 2005, 65:1988
10. Plested CP, Tang T, Spreadbury I, Littleton ET, Kishore U, Vincent A: AChR phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology 2002, 59:1682-1688
11. Zhang X, Yang M, Xu J, Zhang M, Lang B, Wang W, Vincent A: Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry 2007, 78:386-390
12. Spreadbury I, Kishore U, Beeson D, Vincent A: Inhibition of acetylcholine receptor function by seronegative myasthenia gravis non-IgG factor correlates with desensitization. J Neuroimmunol 2005, 162:149-156
13. Berrih S, Morel E, Gaud C, Raimond F, Le Brigand H, Bach JF: Anti-AChR antibodies, thymic histology, and T cell subsets in myasthenia gravis. Neurology 1984, 34:66-71
14. Schluep M, Willcox N, Ritter MA, Newsom-Davis J, Larche M, Brown AN: Myasthenia gravis thymus: clinical, histological and culture correlations. J Autoimmun 1988, 1:445-467
15. Roxanis I, Micklem K, McConville J, Newsom-Davis J, Willcox N: Thymic myoid cells and germinal center formation in myasthenia gravis; possible roles in pathogenesis. J Neuroimmunol 2002, 125:185-197
16. Roxanis I, Micklem K, Willcox N: True epithelial hyperplasia in the thymus of early-onset myasthenia gravis patients: implications for immunopathogenesis. J Neuroimmunol 2001, 112:163-173
17. Shiono H, Roxanis I, Zhang W, Sims GP, Meager A, Jacobson LW, Liu JL, Matthews I, Wong YL, Bonifati M, Micklem K, Stott DI, Todd JA, Beeson D, Vincent A, Willcox N: Scenarios for autoimmunization of T and B cells in myasthenia gravis. Ann NY Acad Sci 2003, 998:237-256
18. Flores KG, Li J, Sempowski GD, Haynes BF, Hale LP: Analysis of the human thymic perivascular space during aging. J Clin Invest 1999, 104:1031-1039
19. Castleman B, Norris EH: The pathology of the thymus in myasthenia gravis: a study of 35 cases. Medicine 1949, 28:27-58
20. Wakkach A, Guyon T, Bruand C, Tzartos S, Cohen-Kaminsky S, Berrih-Aknin S: Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis. J Immunol 1996, 157:3752-3760
21. MacLennan CA, Beeson D, Willcox N, Vincent A, Newsom-Davis J: Muscle nicotinic acetylcholine receptor mRNA expression in hyperplastic and neoplastic myasthenia gravis thymus. Ann NY Acad Sci 1998, 841:407-410
22. Schluep M, Willcox N, Vincent A, Dhoot GK, Newsom-Davis J: Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann Neurol 1987, 22:212-222
23. Wekerle H, Ketelsen UP: Intrathymic pathogenesis and dual genetic control of myasthenia gravis. Lancet 1977, 1:678-680
24. Nakano S, Engel AG: Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 1993, 43:1167-1172
25. Leite MI, Strobel P, Jones M, Micklem K, Moritz R, Gold R, Niks EH, Berrih-Aknin S, Scaravilli F, Canelhas A, Marx A, Newsom-Davis J, Willcox N, Vincent A: Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005, 57:444-448
26. Lauriola L, Ranelletti F, Maggiano N, Guerriero M, Punzi C, Marsili F, Bartoccioni E, Evoli A: Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005, 64:536-538
27. Beeson D, Jacobson L, Newsom-Davis J, Vincent A: A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis. Neurology 1996, 47:1552-1555
28. Pratt JR, Basheer SA, Sacks SH: Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002, 8:582-587
29. Monsinjon T, Gasque P, Chan P, Ischenko A, Brady JJ, Fontaine MC: Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 2003, 17:1003-1014
30. Hsi BL, Yeh CJ, Fenichel P, Samson M, Grivaux C: Monoclonal antibody GB24 recognizes a trophoblast-lymphocyte cross-reactive antigen. Am J Reprod Immunol Microbiol 1988, 18:21-27
31. Adams EM, Brown MC, Nunge M, Krych M, Atkinson JP: Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity. J Immunol 1991, 147:3005-3011
32. Davies CS, Harris CL, Morgan BP: Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects. Immunology 2005, 114:280-286
33. Morgan BP: Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 1989, 264:1-14
34. Morgan BP, Meri S: Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994, 15:369-396
35. Lampert IA, Schofield JB, Amlot P, Van Noorden S: Protection of germinal centres from complement attack: decay-accelerating factor (DAF) is a constitutive protein on follicular dendritic cells. A study in reactive and neoplastic follicles. J Pathol 1993, 170:115-120
36. French LE, Sappino AP, Tschopp J, Schifferli JA: Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus. J Clin Invest 1992, 90:1919-1925
37. Meraouna A, Cizeron-Clairac G, Panse RL, Bismuth J, Truffault F, Tallaksen C, Berrih-Aknin S: The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 2006, 108:432-440
38. Sprott H, Muller-Ladner U, Distler O, Gay RE, Barnum SR, Landthaler M, Scholmerich J, Lang B, Gay S: Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma). J Rheumatol 2000, 27:402-404
39. van Beek J, van Meurs M, t Hart BA, Brok HP, Neal JW, Chatagner A, Harris CL, Omidvar N, Morgan BP, Laman JD, Gasque P: Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation. J Immunol 2005, 174:2353-2365
40. Mason JC, Yarwood H, Sugars K, Morgan BP, Davies KA, Haskard DO: Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood 1999, 94:1673-1682
41. Safar D, Aime C, Cohen-Kaminsky S, Berrih-Aknin S: Antibodies to thymic epithelial cells in myasthenia gravis. J Neuroimmunol 1991, 35:101-110
42. Kyewski B, Klein L: A central role for central tolerance. Annu Rev Immunol 2006, 24:571-606
43. Daveau M, Benard M, Scotte M, Schouft MT, Hiron M, Francois A, Salier JP, Fontaine M: Expression of a functional C5a receptor in regenerating hepatocytes and its involvement in a proliferative signaling pathway in rat. J Immunol 2004, 173:3418-3424
44. Fosbrink M, Niculescu F, Rus V, Shin ML, Rus H: C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1. J Biol Chem 2006, 281:19009-19018
45. Rus HG, Niculescu FI, Shin ML: Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol Rev 2001, 180:49-55
46. Cole DS, Morgan BP: Beyond lysis: how complement influences cell fate. Clin Sci (Lond) 2003, 104:455-466
47. Dashiell SM, Rus H, Koski CL: Terminal complement complexes concomitantly stimulate proliferation and rescue of Schwann cells from apoptosis. Glia 2000, 30:187-198
48. Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME: Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest 2002, 110:1269-1274
49. Kaminski HJ, Kusner LL, Richmonds C, Medof ME, Lin F: Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Exp Neurol 2006, 202:287-293
50. Morgan BP, Chamberlain-Banoub J, Neal JW, Song W, Mizuno M, Harris CL: The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol 2006, 146:294-302
51. Kaminski HJ, Li Z, Richmonds C, Lin F, Medof ME: Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp Neurol 2004, 189:333-342
52. Navenot JM, Villanova M, Lucas-Heron B, Malandrini A, Blanchard D, Louboutin JP: Expression of CD59, a regulator of the membrane attack complex of complement, on human skeletal muscle fibers. Muscle Nerve 1997, 20:92-96
53. Gasque P, Neal JW, Singhrao SK, McGreal EP, Dean YD, Van BJ, Morgan BP: Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities. Mol Neurobiol 2002, 25:1-17
54. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs KM, Smith RJ, Silvestri G, Russell SR, Klaver CC, Barbazetto I, Chang S, Yannuzzi LA, Barile GR, Merriam JC, Smith RT, Olsh AK, Bergeron J, Zernant J, Merriam JE, Gold B, Dean M, Allikmets R: A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005, 102:7227-7232
55. MacLennan IC: Germinal centers. Annu Rev Immunol 1994, 12:117-139
56. Sims GP, Shiono H, Willcox N, Stott DI: Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J Immunol 2001, 167:1935-1944
57. Matthews I, Sims G, Ledwidge S, Stott D, Beeson D, Willcox N, Vincent A: Antibodies to acetylcholine receptor in parous women with myasthenia: evidence for immunization by fetal antigen. Lab Invest 2002, 82:1407-1417
58. Graus YF, de Baets MH, Parren PW, Berrih-Aknin S, Wokke J, van Breda Vriesman PJ, Burton DR: Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. J Immunol 1997, 158:1919-1929
59. Leite M, Cossins J, Clover L, Beeson D, Willcox N, Vincent A: Antibodies to clustered AChR and thymic changes in seronegative myasthenia gravis (abstract). J Neurol Neurosurg Psychiatry (in press)
60. Vincent A, Lang B; International Seronegative Myasthenia Gravis Survey: The prevalence of MuSK antibody positive myasthenia gravis worldwide. J Neuroimmunol 2006, 178:233